Company Overview and News
A new report from Dutch digital security firm Gemalto claims that as many has one billion Aadhar records were breached in just the first six months of 2018.
Good day and welcome to the Gemalto First Quarter 2018 Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Philippe Vallée, Gemalto CEO. Please go ahead, sir.
ATOS SE agreed to buy Syntel, Inc. in a $3.4-billion cash deal to boost the French computer-services provider’s US access, to customers including financials like American Express Co. and State Street Corp.
BNPZY STT BNPQY FDX BNPQF GTO ATONV
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SYNT BNPZY STT BNPQY FDX BNPQF GTO ATONV
2018-04-29 seekingalpha - 2
Good afternoon and welcome to our 2018 First Quarter Revenue Call. I'm Philippe Vallée the CEO of Gemalto. And today, I'm with Virginie Dupérat-Vergne, our CFO; and Jean-Claude Deturche, our Investor Relations Officer. Together, we will commenting the presentation that you can download from our website. We will begin the key elements of the release, and then we will take your questions. So after having carefully read the information on Page 2 and Page 3, I invite you to go to Page 5 to the highlights of this first quarter.
April 3 (Reuters) - Britain’s FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers, with futures down 1.15 percent ahead of the cash market open.
ESL MRO HSB DLUEY MLSRF HSBC MLSPF HBCYF FOX CGEN AAL 533264 HCS DELRF VEDL 0005 MLSPY VED DLAR AAUKF HSEA HSEB FOXA NGLOY GTO
April 3 (Reuters) - Britain’s FTSE 100 index is seen opening 46 points lower at 7,011 on Tuesday, according to financial bookmakers.
ESL MRO HSB DLUEY MLSRF HSBC MLSPF HBCYF CGEN AAL 533264 HCS DELRF VEDL 0005 MLSPY VED DLAR AAUKF HSEA HSEB NGLOY GTO
(Reuters) - British passport-making company De La Rue Plc is set to challenge the British government’s decision that allows Franco-Dutch company Gemalto NV to make new blue national passports from 2019, the Financial Times reported on Monday.
DLAR DLUEY GTO DELRF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:GTO / GEMALTO on message board site Silicon Investor.